ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
24.81
+1.38 (5.89%)
At close: Mar 9, 2026, 4:00 PM EDT
24.81
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:10 PM EDT

ArriVent BioPharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
1,097854898--
Market Cap Growth
18.82%-4.88%---
Enterprise Value
792.68541.32679.100
Last Close Price
24.8120.1226.64--
PE Ratio
--4.66-10.41--
PB Ratio
3.242.783.49--
P/TBV Ratio
3.112.523.25--
P/FCF Ratio
--5.32-12.79--
P/OCF Ratio
--5.32-12.79--
EV/EBITDA Ratio
--3.05-7.20--
EV/EBIT Ratio
--3.05-7.20--
EV/FCF Ratio
--3.37-9.67--
Debt / Equity Ratio
-00.000.000.00
Debt / EBITDA Ratio
000.000.000.00
Debt / FCF Ratio
000.00-0.010.00
Net Debt / Equity Ratio
-1.02-1.02-0.850.981.92
Net Debt / EBITDA Ratio
1.761.762.322.014.42
Net Debt / FCF Ratio
1.951.953.122.693.74
Quick Ratio
12.0612.0612.6712.9419.54
Current Ratio
12.8312.8313.1413.7621.84
Return on Equity (ROE)
-58.88%-58.88%-39.36%-64.18%-56.99%
Return on Assets (ROA)
-58.39%-58.39%-43.06%-43.12%-20.19%
Return on Invested Capital (ROIC)
-1063.59%-1063.59%-469.29%-1197.85%-328.67%
Return on Capital Employed (ROCE)
-62.86%-62.86%-46.10%-45.77%-21.15%
Earnings Yield
-15.04%-21.47%-9.61%--
FCF Yield
--18.80%-7.82%--
Buyback Yield / Dilution
-23.78%-23.78%-20.78%--
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q